This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006;63:679–85.OlfsonMBlancoCLiuLMorenoCLajeG.National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. 2006;63:679–85.10.1001/archpsyc.63.6.67916754841Search in Google Scholar
Olfson M, Blanco C, Liu S, Wang S, Correll CU. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry 2012;69:1247–56.OlfsonMBlancoCLiuSWangSCorrellCU. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. 2012;69:1247–56.10.1001/archgenpsychiatry.2012.64722868273Search in Google Scholar
Patten SB, Waheed W, Bresee L. A review of pharmacoepidemiologic studies of antipsychotic use in children and adolescents. Can J Psychiatry 2012;57:717–21.PattenSBWaheedWBreseeL.A review of pharmacoepidemiologic studies of antipsychotic use in children and adolescents. 2012;57:717–21.10.1177/07067437120570120223228229Search in Google Scholar
Hartz I, Skurtveit S, Steffenak AKM, Karlstad O, Handal M. Psychotropic drug use among 0-17 year olds during 2004-2014: a nationwide prescription database study. BMC Psychiatry 2016;16:12.HartzISkurtveitSSteffenakAKMKarlstadOHandalM.Psychotropic drug use among 0-17 year olds during 2004-2014: a nationwide prescription database study. 2016;16:12.10.1186/s12888-016-0716-x473194726822371Search in Google Scholar
Saastamoinen LK, Autti-Rämö I, Tuulio-Henriksson A, Sourander A. Prescribing of antipsychotics for children and adolescents is increasing in Finland. Finnish Medical J 2017;72:575–9.SaastamoinenLKAutti-RämöITuulio-HenrikssonASouranderA.Prescribing of antipsychotics for children and adolescents is increasing in Finland. 2017;72:575–9.Search in Google Scholar
Steinhausen H. Recent international trends in psychotropic medication prescriptions for children and adolescents. Eur Child Adolesc Psychiatry 2015;24:635–40.SteinhausenH.Recent international trends in psychotropic medication prescriptions for children and adolescents. 2015;24:635–40.10.1007/s00787-014-0631-y25378107Search in Google Scholar
Crystal S, Mackie T, Fenton MC, Amin S, Neese-Todd S, Olfson M, et al. Rapid growth of antipsychotic prescriptions for children who are publicly insured has ceased, but concerns remain. Health Affairs 2016;35:974–82.CrystalSMackieTFentonMCAminSNeese-ToddSOlfsonM, . Rapid growth of antipsychotic prescriptions for children who are publicly insured has ceased, but concerns remain. 2016;35:974–82.10.1377/hlthaff.2016.006427269012Search in Google Scholar
Olfson M, King M, Schoenbaum M. Treatment of young people with antipsychotic medications in the United States. JAMA Psychiatry 2015;72:867–74.OlfsonMKingMSchoenbaumM.Treatment of young people with antipsychotic medications in the United States. 2015;72:867–74.10.1001/jamapsychiatry.2015.050026132724Search in Google Scholar
Rani F, Murray ML, Byrne PJ, Wong ICK. Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 2008;121:1002–9.RaniFMurrayMLByrnePJWongICK. Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. 2008;121:1002–9.10.1542/peds.2007-200818450906Search in Google Scholar
Verdoux H, Tournier M, Begaud B. Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand 2010;121:4–10.VerdouxHTournierMBegaudB.Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. 2010;121:4–10.10.1111/j.1600-0447.2009.01425.x20059452Search in Google Scholar
Talka A-K, Kumpulainen K. Psychotropic medication use in children in urgent psychiatric inpatient care. Finnish Medical J 2015;70:33–8.Talka A-K, KumpulainenK.Psychotropic medication use in children in urgent psychiatric inpatient care. 2015;70:33–8.Search in Google Scholar
US Food and Drug Administration. Drugs@FDA: FDA approved drug products. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfmUS Food and Drug Administration. . Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfmSearch in Google Scholar
Park SY, Cervesi C, Galling B, Molteni S, Walyzada F, Ameis SH, et al. Antipsychotic use trends in youth with autism spectrum disorder and/or intellectual disability: a meta-analysis. J Am Acad Child Adolesc Psychiatry 2016;55:468.e4.ParkSYCervesiCGallingBMolteniSWalyzadaFAmeisSH, . Antipsychotic use trends in youth with autism spectrum disorder and/or intellectual disability: a meta-analysis. 2016;55:468.e4.10.1016/j.jaac.2016.03.01227238064Search in Google Scholar
Pappadopulos E, Rosato NS, Correll CU, Findling RL, Lucas J, Crystal S, et al. Experts’ recommendations for treating maladaptive aggression in youth. J Child Adolesc Psychopharmacol 2011;21:505–15.PappadopulosERosatoNSCorrellCUFindlingRLLucasJCrystalS, . Experts’ recommendations for treating maladaptive aggression in youth. 2011;21:505–15.10.1089/cap.2010.0128327971622196314Search in Google Scholar
Cloitre M, Stolbach BC, Herman JL, van der Kolk B, Pynoos R, Wang J, et al. A developmental approach to complex PTSD: Childhood and adult cumulative trauma as predictors of symptom complexity. J Traum Stress 2009;22:399–408.CloitreMStolbachBCHermanJLvan der KolkBPynoosRWangJ, . A developmental approach to complex PTSD: Childhood and adult cumulative trauma as predictors of symptom complexity. 2009;22:399–408.10.1002/jts.2044419795402Search in Google Scholar
Dvir YF, Julian D, Hill MF, Jean A. Childhood maltreatment, emotional dysregulation, and psychiatric comorbidities. Harv Rev Psychiatry 2014;22:149–61.DvirYFJulianDHillMFJeanA.Childhood maltreatment, emotional dysregulation, and psychiatric comorbidities. 2014;22:149–61.10.1097/HRP.0000000000000014409182324704784Search in Google Scholar
Ellonen N, Piispa M, Peltonen K, Oranen M. Exposure to parental violence and outcomes of child psychosocial adjustment. Violence Vict 2013;28:3–15.EllonenNPiispaMPeltonenKOranenM.Exposure to parental violence and outcomes of child psychosocial adjustment. 2013;28:3–15.10.1891/0886-6708.28.1.323520829Search in Google Scholar
Benarous X, Raffin M, Bodeau N, Dhossche D, Cohen D, Consoli A. Adverse childhood experiences among inpatient youths with severe and early-onset psychiatric disorders: Prevalence and clinical correlates. Child Psychiatry Hum Dev 2017;48:248–59.BenarousXRaffinMBodeauNDhosscheDCohenDConsoliA.Adverse childhood experiences among inpatient youths with severe and early-onset psychiatric disorders: Prevalence and clinical correlates. 2017;48:248–59.10.1007/s10578-016-0637-427002816Search in Google Scholar
Ford JD, Gagnon K, Connor DF, Pearson G. History of interpersonal violence, abuse, and nonvictimization trauma and severity of psychiatric symptoms among children in outpatient psychiatric treatment. J Interpers Violence 2011;26:3316–37.FordJDGagnonKConnorDFPearsonG.History of interpersonal violence, abuse, and nonvictimization trauma and severity of psychiatric symptoms among children in outpatient psychiatric treatment. 2011;26:3316–37.10.1177/088626051039300921362676Search in Google Scholar
Ching H, Pringsheim T. Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2012;5:CD009043.ChingHPringsheimT.Aripiprazole for autism spectrum disorders (ASD). 2012;5:CD009043.10.1002/14651858.CD009043.pub222592735Search in Google Scholar
Doyle CA, McDougle CJ. Pharmacotherapy to control behavioral symptoms in children with autism. Expert Opin Pharmacother 2012;13:1615–29.DoyleCAMcDougleCJ. Pharmacotherapy to control behavioral symptoms in children with autism. 2012;13:1615–29.10.1517/14656566.2012.67411022550944Search in Google Scholar
Seida JC, Schouten JR, Boylan K, Newton AS, Mousavi SS, Beaith A, et al. Antipsychotics for children and young adults: a comparative effectiveness review. Pediatrics 2012; 129:e771-84.SeidaJCSchoutenJRBoylanKNewtonASMousaviSSBeaithA, . Antipsychotics for children and young adults: a comparative effectiveness review. 2012; 129:e771-84.10.1542/peds.2011-215822351885Search in Google Scholar
Hirsch LE, Pringsheim T. Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2016;6:CD009043.HirschLEPringsheimT.Aripiprazole for autism spectrum disorders (ASD). 2016;6:CD009043.10.1002/14651858.CD009043.pub3712022027344135Search in Google Scholar
Ji NY, Findling RL. An update on pharmacotherapy for autism spectrum disorder in children and adolescents. Curr Opin Psychiatry 2015;28:91–101.JiNYFindlingRL. An update on pharmacotherapy for autism spectrum disorder in children and adolescents. 2015;28:91–101.10.1097/YCO.000000000000013225602248Search in Google Scholar
McQuire C, Hassiotis A, Harrison B, Pilling S. Pharmacological interventions for challenging behaviour in children with intellectual disabilities: a systematic review and meta-analysis. BMC Psychiatry 2015;15:303.McQuireCHassiotisAHarrisonBPillingS.Pharmacological interventions for challenging behaviour in children with intellectual disabilities: a systematic review and meta-analysis. 2015;15:303.10.1186/s12888-015-0688-2466203326611280Search in Google Scholar
Pringsheim T, Hirsch L, Gardner D, Gorman DA. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: A systematic review and meta-analysis. Part 2: Antipsychotics and traditional mood stabilizers. Can J Psychiatry 2015;60:52–61.PringsheimTHirschLGardnerDGormanDA. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: A systematic review and meta-analysis. Part 2: Antipsychotics and traditional mood stabilizers. 2015;60:52–61.10.1177/070674371506000203434494725886656Search in Google Scholar
Loy JH, Merry SN, Hetrick SE, Stasiak K. Atypical antipsychotics for disruptive behaviour disorders in children and youths. Cochrane Database Syst Rev 2012;9:CD008559.LoyJHMerrySNHetrickSEStasiakK.Atypical antipsychotics for disruptive behaviour disorders in children and youths. 2012;9:CD008559.10.1002/14651858.CD008559.pub222972123Search in Google Scholar
Yang C, Huang H, Zhang L, Zhu C, Guo Q. Aripiprazole for the treatment of tic disorders in children: a systematic review and meta-analysis. BMC Psychiatry 2015;15:179.YangCHuangHZhangLZhuCGuoQ.Aripiprazole for the treatment of tic disorders in children: a systematic review and meta-analysis. 2015;15:179.10.1186/s12888-015-0504-z451863026220447Search in Google Scholar
Roessner V, Schoenefeld K, Buse J, Bender S, Ehrlich S, Münchau A. Pharmacological treatment of tic disorders and Tourette syndrome. Neuropharmacology 2013;68:143–9.RoessnerVSchoenefeldKBuseJBenderSEhrlichSMünchauA.Pharmacological treatment of tic disorders and Tourette syndrome. 2013;68:143–9.10.1016/j.neuropharm.2012.05.04322728760Search in Google Scholar
Fraguas D, Correll CU, Merchan-Naranjo J, Rapado-Castro M, Parellada M, Moreno C, et al. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol 2011;21:621–45.FraguasDCorrellCUMerchan-NaranjoJRapado-CastroMParelladaMMorenoC, . Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons. 2011;21:621–45.10.1016/j.euroneuro.2010.07.00220702068Search in Google Scholar
Stafford MR, Mayo-Wilson E, Loucas CE, James A, Hollis C, Birchwood M, et al. Efficacy and safety of pharmacological and psychological interventions for the treatment of psychosis and schizophrenia in children, adolescents and young adults: A systematic review and meta-analysis. PLoS One 2015;10:e0117166.StaffordMRMayo-WilsonELoucasCEJamesAHollisCBirchwoodM, . Efficacy and safety of pharmacological and psychological interventions for the treatment of psychosis and schizophrenia in children, adolescents and young adults: A systematic review and meta-analysis. 2015;10:e0117166.10.1371/journal.pone.0117166432483325671707Search in Google Scholar
Schimmelmann BG, Schmidt SJ, Carbon M, Correll CU. Treatment of adolescents with early-onset schizophrenia spectrum disorders: In search of a rational, evidence-informed approach. Curr Opin Psychiatry 2013;26:219–30.SchimmelmannBGSchmidtSJCarbonMCorrellCU. Treatment of adolescents with early-onset schizophrenia spectrum disorders: In search of a rational, evidence-informed approach. 2013;26:219–30.10.1097/YCO.0b013e32835dcc2a23364281Search in Google Scholar
Kirino E. Efficacy and safety of aripiprazole in child and adolescent patients. Eur Child Adolesc Psychiatry 2012;21:361-8.KirinoE.Efficacy and safety of aripiprazole in child and adolescent patients. 2012;21:361-8.10.1007/s00787-012-0270-0338960122447196Search in Google Scholar
Correll CU, Kratochvil CJ. Antipsychotic use in children and adolescents: Minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 2008;47:9–20.CorrellCUKratochvilCJ. Antipsychotic use in children and adolescents: Minimizing adverse effects to maximize outcomes. 2008;47:9–20.10.1097/chi.0b013e31815b5cb118174821Search in Google Scholar
Ben Amor L. Antipsychotics in pediatric and adolescent patients: A review of comparative safety data. J Affect Disord 2012;138(Suppl):S22-S30.Ben AmorL.Antipsychotics in pediatric and adolescent patients: A review of comparative safety data. 2012;138(Suppl):S22-S30.10.1016/j.jad.2012.02.03022405602Search in Google Scholar
Pringsheim T, Lam D, Ching H, Patten S. Metabolic and neurological complications of second-generation antipsychotic use in children: A systematic review and meta-analysis of randomized controlled trials. Drug Saf 2011;34:651–68.PringsheimTLamDChingHPattenS.Metabolic and neurological complications of second-generation antipsychotic use in children: A systematic review and meta-analysis of randomized controlled trials. 2011;34:651–68.10.2165/11592020-000000000-0000021751826Search in Google Scholar
De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. European Psychiatry: the Journal of the Association of Eur Psychiatry 2011;26:144–58.De HertMDobbelaereMSheridanEMCohenDCorrellCU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. 2011;26:144–58.10.1016/j.eurpsy.2010.09.01121295450Search in Google Scholar
Martinez-Ortega JM, Funes-Godoy S, Diaz-Atienza F, Gutierrez-Rojas L, Perez-Costillas L, Gurpegui M. Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review. Eur Child Adolesc Psychiatry 2013;22:457–79.Martinez-OrtegaJMFunes-GodoySDiaz-AtienzaFGutierrez-RojasLPerez-CostillasLGurpeguiM.Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review. 2013;22:457–79.10.1007/s00787-013-0399-523503976Search in Google Scholar
Pringsheim T, Panagiotopoulos C, Davidson J, Ho J. Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) guideline group. Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatr Child Health 2011;16:581–9.PringsheimTPanagiotopoulosCDavidsonJHoJ.Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) guideline group. Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. 2011;16:581–9.10.1093/pch/16.9.581Search in Google Scholar
American Academy of Child and Adolescent Psychiatry. Practice parameter for the use of atypical antipsychotic medications in children and adolescents. 2011. Available at: www.aacap.org.American Academy of Child and Adolescent Psychiatry. . 2011. Available at: www.aacap.orgSearch in Google Scholar
Kealey E, Scholle SH, Byron SC, Hoagwood K, Leckman-Westin E, Kelleher K, et al. Quality concerns in antipsychotic prescribing for youth: A review of treatment guidelines. Acad Pediatr 2014;14(Suppl):S68-S75.KealeyEScholleSHByronSCHoagwoodKLeckman-WestinEKelleherK, . Quality concerns in antipsychotic prescribing for youth: A review of treatment guidelines. 2014;14(Suppl):S68-S75.10.1016/j.acap.2014.05.009448632325169461Search in Google Scholar
National Collaborating Centre for Mental Health (UK). Psychosis and schizophrenia in children and young people: Recognition and management. Leicester (UK): British Psychological Society; 2013.National Collaborating Centre for Mental Health (UK). . Leicester (UK): British Psychological Society; 2013.Search in Google Scholar
Ronsley R, Rayter M, Smith D, Davidson J, Panagiotopoulos C. Metabolic monitoring training program implementation in the community setting was associated with improved monitoring in second-generation antipsychotic-treated children. Can J Psychiatry 2012;57:292–9.RonsleyRRayterMSmithDDavidsonJPanagiotopoulosC.Metabolic monitoring training program implementation in the community setting was associated with improved monitoring in second-generation antipsychotic-treated children. 2012;57:292–9.10.1177/07067437120570050422546061Search in Google Scholar
Pasha N, Saeed S, Drewek K. Monitoring of physical health parameters for inpatients on a child and adolescent mental health unit receiving regular antipsychotic therapy. BMJ Qual Improv Rep 2015;4:u202645.w3700.PashaNSaeedSDrewekK.Monitoring of physical health parameters for inpatients on a child and adolescent mental health unit receiving regular antipsychotic therapy. 2015;4:u202645.w3700.10.1136/bmjquality.u202645.w3700469596326734455Search in Google Scholar
Raebel MA, Penfold R, McMahon AW, Reichman M, Shetterly S, Goodrich G, et al. Adherence to guidelines for glucose assessment in starting second-generation antipsychotics. Pediatrics 2014;134:e1308-14.RaebelMAPenfoldRMcMahonAWReichmanMShetterlySGoodrichG, . Adherence to guidelines for glucose assessment in starting second-generation antipsychotics. 2014;134:e1308-14.10.1542/peds.2014-082825287454Search in Google Scholar
Rodday AM, Parsons SK, Mankiw C, Correll CU, Robb AS, Zima BT, et al. Child and adolescent psychiatrists’ reported monitoring behaviors for second-generation antipsychotics. J Child Adolesc Psychopharmacol 2015;25:351–61.RoddayAMParsonsSKMankiwCCorrellCURobbASZimaBT, . Child and adolescent psychiatrists’ reported monitoring behaviors for second-generation antipsychotics. 2015;25:351–61.10.1089/cap.2014.0156444259825918843Search in Google Scholar
Devlin AM, Panagiotopoulos C. Metabolic side effects and pharmacogenetics of second-generation antipsychotics in children. Pharmacogenomics 2015;16:981–96.DevlinAMPanagiotopoulosC.Metabolic side effects and pharmacogenetics of second-generation antipsychotics in children. 2015;16:981–96.10.2217/pgs.15.5526107755Search in Google Scholar
Chowdhury NI, Remington G, Kennedy JL. Genetics of antipsychotic-induced side effects and agranulocytosis. Curr Psychiatry Rep 2011;13:156–65.ChowdhuryNIRemingtonGKennedyJL. Genetics of antipsychotic-induced side effects and agranulocytosis. 2011;13:156–65.10.1007/s11920-011-0185-321336863Search in Google Scholar
Saari A, Sankilampi U, Hannila M, Kiviniemi V, Kesseli K, Dunkel L. New Finnish growth references for children and adolescents aged 0 to 20 years: Length/height-for-age, weight-for-length/height, and body mass index-for-age. Ann Med 2011;43:235–48.SaariASankilampiUHannilaMKiviniemiVKesseliKDunkelL.New Finnish growth references for children and adolescents aged 0 to 20 years: Length/height-for-age, weight-for-length/height, and body mass index-for-age. 2011;43:235–48.10.3109/07853890.2010.51560320854213Search in Google Scholar
World Health Organisation. International Statistical Classification of Diseases and Related Health Problems 10th Revision. 1994. Available at: http://apps.who.int/classifications/icd10/browse/2016/enWorld Health Organisation. . 1994. Available at: http://apps.who.int/classifications/icd10/browse/2016/enSearch in Google Scholar
Rodday AM, Parsons SK, Correll CU, Robb AS, Zima BT, Saunders TS, et al. Child and adolescent psychiatrists’ attitudes and practices prescribing second generation antipsychotics. J Child Adolesc Psychopharmacol 2014;24:90–3.RoddayAMParsonsSKCorrellCURobbASZimaBTSaundersTS, . Child and adolescent psychiatrists’ attitudes and practices prescribing second generation antipsychotics. 2014;24:90–3.10.1089/cap.2013.0133396738724679174Search in Google Scholar